Paper87614
Combination chemotherapy with cis-diammine-dichloro-platinum, vinblastine, and bleomycin in advanced testicular non-seminoma.
Stoter G and 7 others. Lancet, 1979. Cited by 94 papers, by iCite.
Cite this record
ConductScience Library. Combination chemotherapy with cis-diammine-dichloro-platinum, vinblastine, and bleomycin in advanced testicular non-seminoma. Papers, record 87614. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/87614
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Combination chemotherapy with cis-diammine-dichloro-platinum, vinblastine, and bleomycin in advanced testicular non-seminoma.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Teratoma | Major topic |
| Testicular Neoplasms | Major topic |
| Adolescent | |
| Adult | |
| Bleomycin | |
| Cisplatin | |
| Drug Evaluation | |
| Drug Therapy, Combination | |
| Humans | |
| Male | |
| Middle Aged | |
| Neoplasm Staging | |
| Remission, Spontaneous | |
| Vinblastine |
Source PubMed
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 94 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 24750393 | The timing of introduction of pharmaceutical innovations in seven European countries. | J Eval Clin Pract | 2014 | https://conductscience.org/library/papers/24750393 | PubMed |
| 7426343 | Chemotherapy of advanced malignant teratomas. | Br J Cancer | 1980 | https://conductscience.org/library/papers/7426343 | PubMed |
| 7201356 | Nephrotoxicity of cis-diamminedichloride platinum (CDDP) during remission-induction and maintenance chemotherapy of testicular carcinoma. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7201356 | PubMed |
| 6207949 | Antipyrine metabolism in patients with disseminated testicular cancer and the influence of cytostatic treatment. | Cancer Chemother Pharmacol | 1984 | https://conductscience.org/library/papers/6207949 | PubMed |
| 6156025 | Commentary: combination chemotherapy of nonseminomatous testicular cancer. | Cancer Chemother Pharmacol | 1980 | https://conductscience.org/library/papers/6156025 | PubMed |
| 3909096 | Cisplatin: a review of clinical applications and renal toxicity. | Pharm Weekbl Sci | 1985 | https://conductscience.org/library/papers/3909096 | PubMed |
| 3204109 | Absence of relation between nutritional parameters and renal function in non-seminomatous testicular cancer patients. | J Cancer Res Clin Oncol | 1988 | https://conductscience.org/library/papers/3204109 | PubMed |
| 2582119 | Chemotherapy for non-seminomatous germ-cell tumours. | J R Soc Med | 1985 | https://conductscience.org/library/papers/2582119 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/87614
GET https://conductscience.org/api/papers/v1/87614/authors